PMID- 12721760
OWN - NLM
STAT- MEDLINE
DCOM- 20030627
LR  - 20151119
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 51
IP  - 4
DP  - 2003 Apr
TI  - Circulating angiogenic growth factor levels in mice bearing human tumors using 
      Luminex Multiplex technology.
PG  - 321-7
AB  - Tumor angiogenesis is essential for tumor growth and metastasis formation. 
      Luminex methodology was used to measure the levels of four angiogenic cytokines 
      in cell culture medium and in the plasma of mice bearing human tumors. We 
      obtained plasma and conditioned culture medium from 12 different human tumor cell 
      lines. Tumor necrosis factor-alpha (TNF-alpha), basic fibroblast growth factor 
      (bFGF), vascular endothelial growth factor (VEGF), and transforming growth 
      factor-beta (TGF-beta) were determined by the Luminex FlowMetrix assay. VEGF, 
      TNF-alpha, and bFGF were undetectable in non-tumor-bearing animals. HS746T 
      gastric cancer and Caki-1 renal cell cancer cells in culture produced high levels 
      of VEGF (1000 and 450 pg/10(6) cells, respectively). High levels of TGF-beta were 
      produced by HS746T gastric carcinoma and Calu-6 non-small-cell lung carcinoma 
      (3000 and 1000 pg/10(6) cells, respectively). Caki-1 renal cell carcinoma and 
      Calu-6 non-small-cell lung carcinoma cells in culture produced high levels of 
      bFGF (42 and 10 pg/10(6) cells, respectively). Caki-1, SW2 SCLC, HCT-116 and 
      HT-29 colon tumors produced high plasma levels of VEGF (200, 220, 42, and 151 
      pg/ml, respectively) and TGF-beta (31, 36, 45, 32 pg/ml, respectively). A 
      positive linear correlation was seen between tumor volume and VEGF in SW2 
      (r=0.87) and Caki-1 (r=0.47) tumors, and a moderate correlation in HCT116 tumors 
      (r=0.3). Angiogenic profiles in the plasma of nude mice bearing human tumors may 
      be useful to identify appropriate biomarkers for antiangiogenic therapy, as 
      diagnostic and prognostic tools, and to monitor the responses of individual 
      tumors to antiangiogenic therapy.
FAU - Keyes, Kristan A
AU  - Keyes KA
AD  - Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.
FAU - Mann, Larry
AU  - Mann L
FAU - Cox, Karen
AU  - Cox K
FAU - Treadway, Patti
AU  - Treadway P
FAU - Iversen, Philip
AU  - Iversen P
FAU - Chen, Yun-Fei
AU  - Chen YF
FAU - Teicher, Beverly A
AU  - Teicher BA
LA  - eng
PT  - Journal Article
DEP - 20030318
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Angiogenesis Inducing Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Endothelial Growth Factors)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Lymphokines)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Vascular Endothelial Growth Factors)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
SB  - IM
MH  - Angiogenesis Inducing Agents/analysis/*blood
MH  - Animals
MH  - Biomarkers, Tumor/analysis/*blood
MH  - Endothelial Growth Factors/blood
MH  - Fibroblast Growth Factor 2/blood
MH  - Humans
MH  - Immunoassay/methods
MH  - Intercellular Signaling Peptides and Proteins/blood
MH  - Lymphokines/blood
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasm Transplantation
MH  - Neoplasms, Experimental/*blood supply/chemistry/*pathology
MH  - *Neovascularization, Pathologic
MH  - Transforming Growth Factor beta/blood
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/analysis
MH  - Vascular Endothelial Growth Factor A
MH  - Vascular Endothelial Growth Factors
EDAT- 2003/05/02 05:00
MHDA- 2003/06/28 05:00
CRDT- 2003/05/02 05:00
PHST- 2002/07/29 00:00 [received]
PHST- 2002/12/04 00:00 [accepted]
PHST- 2003/05/02 05:00 [pubmed]
PHST- 2003/06/28 05:00 [medline]
PHST- 2003/05/02 05:00 [entrez]
AID - 10.1007/s00280-003-0572-5 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2003 Apr;51(4):321-7. doi: 10.1007/s00280-003-0572-5. 
      Epub 2003 Mar 18.